Diclegis 10 mg / 10 mg Delayed Release Oral Tablet
RxNorm 1375954
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1375954 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Diclegis 10 mg / 10 mg Delayed Release Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SYPrescribable
Synonym (SY):
Diclegis (doxylamine succinate 10 mg / pyridoxine hydrochloride 10 mg) Delayed Release Oral Tablet
(Atom ID: 6338150)
PSNPrescribable
Prescribable Name (PSN):
Diclegis 10 mg / 10 mg Delayed Release Oral Tablet
(Atom ID: 6359711)
SBDPrescribable
Semantic Branded Drug (SBD):
Doxylamine succinate 10 mg / pyridoxine hydrochloride 10 mg Delayed Release Oral Tablet [Diclegis]
(Atom ID: 12369264)
SYPrescribable
Synonym (SY):
Doxylamine succinate 10 mg / vit-B6 Hydrochloride 10 mg Delayed Release Oral Tablet [Diclegis]
(Atom ID: 6338149)
SYPrescribable
Synonym (SY):
Doxylamine succinate 10 mg / vitamin B6 Hydrochloride 10 mg Delayed Release Oral Tablet [Diclegis]
(Atom ID: 6338048)
Patient Education
Doxylamine and Pyridoxine
The combination of doxylamine and pyridoxine is used to treat nausea and vomiting in pregnant women whose symptoms have not improved after changing their diet or using other non-medicine treatments. Doxylamine is in a class of medications called antihistamines. It works by blocking the action of certain natural substances in the body that may contribute to nausea and vomiting. Pyridoxine (vitamin B6) is a vitamin. It is given because a lack of pyridoxine in the body may also be a factor in causing nausea and vomiting during pregnancy.
[Learn More]
* Please review the disclaimer below.